Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Greater occurrence of infections correlates with future cancer diagnosis

Greater occurrence of infections correlates with future cancer diagnosis

Health agencies urge continuation of life-saving measles vaccinations

Health agencies urge continuation of life-saving measles vaccinations

New prognostic tool could help improve clinical decision making for leukemia patients

New prognostic tool could help improve clinical decision making for leukemia patients

Cancer-causing mutation also promotes inflammation

Cancer-causing mutation also promotes inflammation

New prognostic tool helps leukemia patients plan for cancer treatment

New prognostic tool helps leukemia patients plan for cancer treatment

Active support for stem cell research is key to alleviate incurable chronic diseases

Active support for stem cell research is key to alleviate incurable chronic diseases

OGT delivers translocation and partial tandem duplication detection with updates to SureSeq NGS portfolio

OGT delivers translocation and partial tandem duplication detection with updates to SureSeq NGS portfolio

New collaboration may lead to future clinical trials to test treatment for leukemia

New collaboration may lead to future clinical trials to test treatment for leukemia

Her genetic test revealed a microscopic problem — and a jumbo price tag

Her genetic test revealed a microscopic problem — and a jumbo price tag

Oral apixaban as effective as dalteparin for treating blood clots in people with cancer

Oral apixaban as effective as dalteparin for treating blood clots in people with cancer

Research could open up new therapeutic strategies for some lung and kidney cancers

Research could open up new therapeutic strategies for some lung and kidney cancers

Weakness in lung and kidney cancer cells could serve as therapeutic target

Weakness in lung and kidney cancer cells could serve as therapeutic target

Roscovitine enhances nuclear enrichment of traditionally cytoplasmic signaling molecules

Roscovitine enhances nuclear enrichment of traditionally cytoplasmic signaling molecules

Despite failures, chemotherapy still promising against fatal pediatric brain cancer

Despite failures, chemotherapy still promising against fatal pediatric brain cancer

YAP signal pathway plays a vital role in the onset of head-and-neck cancer

YAP signal pathway plays a vital role in the onset of head-and-neck cancer

Penn State engineers model genetic mutations causing drug resistance

Penn State engineers model genetic mutations causing drug resistance

3D chromatin landscapes in T cell acute lymphoblastic leukemia important beyond DNA code changes

3D chromatin landscapes in T cell acute lymphoblastic leukemia important beyond DNA code changes

Changes in 3D genetic structure equally important as DNA code mutations in childhood leukemia

Changes in 3D genetic structure equally important as DNA code mutations in childhood leukemia

A review of the literature on acute promyelocytic leukemia

A review of the literature on acute promyelocytic leukemia

Preclinical study characterizes the binding affinity and selectivity of a selective FLT3 inhibitor

Preclinical study characterizes the binding affinity and selectivity of a selective FLT3 inhibitor

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.